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A B S T R A C T
Streptococcus pneumonia is a major cause of morbidity and mortality in children and adults worldwide.
Lack of fully effective pneumococcal vaccines is a problem. Streptococcus pneumoniae exposes on its
surface C-polysaccharide (cell wall polysaccharide, CWPS) and serospeciﬁc capsular polysaccharides,
used in pneumococcal vaccines. We investigated the effect of CWPS and individual capsular
polysaccharides, with regard to activation of subsets of immune cells of healthy controls. Three
different capsular polysaccharides, CWPS and LPS were used for in vitro stimulation of whole blood. Cell
activation (CD69 expression) was assessed in CD4+ and CD4- T cells, NK-like T cells, NK cells and
monocytes by ﬂow cytometry. Cytokine levels in supernatants were quantiﬁed by Cytometric Bead Array
(CBA). CWPS and the capsules activated immune cell subsets, but to different degrees. NK cells and NK-
like T cells showed the strongest activation, followed by monocytes. Among the three capsules, capsule
type 23 induced the strongest activation and cytokine release, followed by type 9 and type 3. This study
increases the understanding of how the human immune system reacts to pneumococcal vaccine
components.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Streptococcus pneumoniae is a leading cause of bacterial
pneumonia, meningitis, and sepsis in children worldwide. Invasive
pneumococcal disease (IPD) is a serious health problem in children
and adults, and causes almost 1 million childhood deaths
worldwide every year. Streptococcus pneumoniae usually colo-
nizes the nasopharynx of healthy children but is less frequently
found as a colonizer in adults.1 According to ﬁgures from WHO,
1.6 million deaths were caused by this agent annually. In Europe
and the USA the annual incidence of invasive pneumococcal
disease ranges from 10 to 100 cases per 100 000 population.
Streptococcus pneumoniae is an encapsulated gram-positive
bacterium. On the surface, the bacteria are covered with a capsular* Corresponding author. Karolinska Institutet, Department of Medicine Solna,
Respiratory Medicine Unit L4:01 Karolinska University Hospital Solna 171
76 Stockholm, SWEDEN Ofﬁce phone +46 8 517 70665; Fax: +46 8 517 75451.
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1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).polysaccharide that is speciﬁc for each serotype. Totally over
94 different serotypes have been described. However, the C-
polysaccharide (cell wall polysaccharide, CWPS), another polysac-
charide on the pneumococcal surface, has the same structure in all
described pneumococcal serotypes, thereby being a common
denominator within this species.
There are two different types of pneumococcal vaccines on the
market today. Whereas one type contains only polysaccharides,
the other contains proteins in addition to polysaccharides
(conjugated vaccine). The polysaccharide vaccine contains 23 of
the most common pathogenic capsular pneumococcal polysac-
charides while the protein conjugated vaccines contain 7 or
13 different pneumococcal capsular polysaccharides. It is known
that polysaccharides are T-cell independent antigens in their
capacity to generate B-cell responses to produce antibodies.2 In
contrast, when the capsule polysaccharides are conjugated to a
protein they generate a T-cell response with memory T cells in
addition to B cells and antibodies.
Because of the evolving antibiotic resistance and the lack of
highly effective pneumococcal vaccines covering all pathogenicciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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involved in the pathogenicity of Streptococcus pneumoniae.3
We hypothesized that the capsular polysaccharides may interact
with several types of immune cells, and that the cell-stimulatory
capacity will vary between different serotypes of these poly-
saccharides, which may in turn affect the serotype-speciﬁc
response induced by vaccination. To investigate the effect of the
individual capsular polysaccharides and C- polysaccharide on the
immune cells and cytokines, we performed whole blood stimula-
tion using type 3-, type 9- and type 23-polysaccharides (all included
in the 23-valent polysaccharide vaccine). Subsequently, the rate of
CD69 expression on immune cell subsets was measured as a marker
of activation. We also measured the concentration of IL-8, IL-10, TNF
and INFg in supernatants of in vitro stimulated blood cells.
2. Materials and methods
2.1. Subjects and blood samples
The persons included in this study were healthy adult non-
pneumococcal vaccinated volunteers, median age 48.5 years, range
42 to 59. Peripheral blood cells were obtained by vein puncture
from ten different non-smoking women. All blood samples were
drawn in early morning. Blood was collected using Vacutainer TM
tubes (Becton-Dickinson Vacutainer Systems, Franklin Lakes, NJ,
U.S.A.) containing sodium heparin anticoagulant. All participants
signed a written informed consent. The study was approved by the
Regional Ethical Review Board, Stockholm, Sweden.
2.2. In vitro stimulation
Each polysaccharide was added to 500 ml whole blood from
healthy subjects. Pneumococcal capsular polysaccharides type 3,
type 9 (9N) and type 23 (23F), (randomly chosen) were purchased
from ATCC, (American Type Culture Collection, USA). CWPS, also
known as CPS (pneumococcal C- polysaccharide) was purchased
from Statens Serum Institute, Copenhagen, Denmark. LPS (E.Coli)
was purchased from Sigma-Aldrich, Schnelldorf, Germany. Whole
blood alone was used as negative control. LPS was used as positive
control. The ﬁnal concentration of each polysaccharide, LPS and
CWPS was 10 mg/ml of blood. Samples were incubated for 4 h
(eight persons) and 12 h (nine persons) respectively in 12-well
microtiter plates in 378C in humidiﬁed atmosphere of 5% CO2.Table 1
CD69 expression was determined as a measure of cell activation after in vitro stimulat
4 h stimulation
CD4+ P CD4- P CD3+CD
Unstim. 165 259 361 
LPS 1385 ** 1873 ** 3228 
CWPS 201 * 375 ** 663 
T3 170 * 289 ** 410 
T9 194 * 356 ** 600 
T23 194 * 368 ** 637 
12 h stimulation
CD4+ P CD4- P CD3+CD
Unstim. 175 312 348 
LPS 1195 ** 2505 ** 3815 
CWPS 205 ** 495 ** 783 
T3 193 NS 329 NS 374 
T9 201 NS 399 ** 631 
T23 226 ** 488 ** 799 
Whole blood from healthy non-pneumococcal vaccinated subjects were stimulated for 4
polysaccharides type 3, type 9 and type 23. Unstimulated whole blood was used as negat
(T-helper), CD3+CD4- T cells (‘‘T-cytotoxic’’), CD3+CD56+ (NK-like T cells), CD3-CD56
expression using ﬂow cytometry. Results are expressed as median values for healthy sub
unstimulated cells. *p < 0.05, **p < 0.01, ***p < 0.001, NS (non signiﬁcant).2.3. Antibodies and ﬂow cytometry
In order to evaluate the activation of different leukocyte
subsets, cells were labelled with the following ﬂuorochrome-
conjugated monoclonal antibodies: anti-CD3-Paciﬁc Blue, anti-
CD56-PE, anti-CD4-APC H7, anti-CD14-PerCP and anti-CD69-FITC.
All antibodies were purchased from BD Biosciences, San Jose, CA,
USA.
Antibodies were added to 50 ml aliquots of blood after in vitro
stimulation. Remaining blood was centrifuged and supernatants
were collected and stored at -208C before analysis of cytokines. The
samples were then incubated with antibodies for 20 min in
darkness at room temperature (RT). Lysing of red blood cells,
ﬁxation and stabilization of white blood cells was achieved
according to the manufacturer’s instructions using COULTER
Multi-Q-prep (Coulter Electronics Inc., Hialeah FL, U.S.A.) Cells
were analysed by ﬂow cytometry (FACS Canto TM II ﬂow
cytometer) (BD). Data was processed using Diva 6.1.2 software
(BD).
In order to gate on lymphocytes and select subsets, forward
scatter (FSC) and side scatter (SSC) in combination with the
following patterns of cell surface marker expression were used
(CD3 is a marker of all T cells): CD3+CD4+, CD3+CD4-, CD3+CD56+
(NK-like T cells) and CD3-CD56+ (NK cells). FSC and SSC in
combination with CD14+ were used in order to gate monocytes.
Although limitations of the ﬂow cytometer available for this
study did not allow us to include staining also for CD8, in order to
determine the proportion of CD8+ cells in the CD4- T cell
population we have investigated this in blood samples from four
individuals, using the same stimuli and at two timepoints (4 h and
8 h). CD8+ T cells constituted on average 86% of the CD4- T cells
(range 77-90%), and this was not altered by the various stimuli.
Cell activation was assessed as expression of CD69 in the
respective subsets. Data are presented as mean ﬂuorescence
intensity (MFI) for CD69, or as relative mean ﬂuorescence intensity
(MFI) for CD69 (i.e. MFI of CD69 for stimulated cells divided by MFI
of CD69 for unstimulated cells).
2.4. Quantiﬁcation of secreted cytokines
The Cytometric Bead Array (CBA) ﬂex set, a multiplex assay
allowing simultaneous detection of several analytes in a small
sample volume, (BD, Franklin Lakes, NJ, USA) was used toion.
56+ P NK P Monocytes P
394 473
** 5193 ** 1426 **
** 1204 ** 711 **
* 562 * 582 **
** 940 ** 638 *
** 1041 ** 746 **
56+ P NK P
284
** 6788 **
** 1047 **
NS 377 **
* 671 **
** 915 **
 h or 12 h with pneumococcal C- polysaccharide (CWPS) and pneumococcal capsular
ive control and stimulation with LPS as positive control. Subsets of CD3+CD4+ T cells
+ (NK cells) and CD14+ cells (monocytes) were identiﬁed and analysed for CD69
jects of mean ﬂuorescence intensity (MFI) values. P values refer to comparisons with
Figure 1. Results from gating of whole blood of healthy controls, (a) gating on lymphocytes, (b) gating on NK cells, (c) gating on T cells, (d) gating on CD4+ T cells in the upper
box and CD4- T cells in the lower box, (e) gating on NK-like T cells.
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supernatants. Brieﬂy, these tests contain micro-particles to
which different anti-cytokine antibodies can be coated. After
incubation with supernatants followed by labelling with a
second ﬂuorescently labelled anti-cytokine antibody, the
amount of cytokines can be analysed. The cytokines measured
were TNF, IL-8, IL-10 and IFNg. 30 ml of all samples were
prepared as described in the protocol and the cytokines were
detected within a range of 10-2500 pg/ml. The assays were
performed according to the manufacturer’s instructions and the
data were analysed using the BD Cytometric Bead Array (BD
Biosciences) software, in a FACS Canto TM II ﬂow cytometer (BD).
The data were analysed with FCAP Array Software version 1-01
(Soft Flow, Inc., St. Louis Park, MN, USA).Figure 2. Cell activation was assessed as expression of CD69 by ﬂow cytometric analysis. T
CWPS and three different pneumococcal capsular polysaccharides. The ﬁgure depicts CD6
3, type 9 and type 23 capsules and negative control and (c) shows LPS and negative contr
of individuals included, N = 9).2.5. Statistical methods and data management
Multiple comparisons of continuous data were performed by
non-parametric analysis of variance. Statistical comparisons in
order to test differences between two dependent observations
were performed by use of the non-parametric Wilcoxon signed-
rank test. In addition to that, descriptive statistics and graphical
methods were used to characterize the data.
The study employs multiple hypotheses testing, where each
hypothesis was analysed separately and the existence of patterns
in and the consistency of the results were considered in the
analysis. All analyses were carried out by use of the SAS system 9.3,
(SAS Institute Inc., Cary, NC, USA) and the 5, 1 and 0.1% levels of
signiﬁcance were considered.he histograms show results after whole blood of healthy controls was stimulated by
9 expression on NK cells where (a) shows CWPS and negative control, (b) shows type
ol. CWPS; pneumococcal cell wall polysaccharide, LPS; lipopolysaccharide. (Number
M. Sundberg-Ko¨vamees et al. / International Journal of Infectious Diseases 52 (2016) 1–84Graphs were drawn using Graph Pad PRISM 5 (GraphPad
Software, Inc. San Diego, CA, USA). P-values < 0.05 were consid-
ered statistically signiﬁcant. *p < 0.05, **p < 0.01, ***p < 0.001, NS
(non signiﬁcant).
3. Results
3.1. CD69 expression after stimulation of whole blood
CWPS as well as the three capsules tested (type 3, type 9 and
type 23) activated all leukocyte cell types investigated to increased
CD69 expression, but to different degrees (Table 1). The cell subsetsFigure 3. (A and B) CD69 expression in cell subsets. CD69 expression was determined as 
pneumococcal vaccinated subjects was stimulated for 4 h (Figure part A, N = 8) or 12 h (F
capsular polysaccharides type 3, type 9 and type 23. Unstimulated whole blood was use
Graphs show CD69 expression in stimulated versus unstimulated cells, expressed as r
comparisons were only carried out between the three capsular polysaccharides (type 3analyzed were CD4+ T cells, CD4- T cells, NK-like (CD56+) T cells,
NK cells and monocytes (ﬁg. 1, ﬁg. 2)
We analyzed CD69 expression after 4 h (ﬁg. 3 part A) and after
12 h (ﬁg. 3 part B). After stimulation with CWPS the highest CD69
relative MFI values were observed for NK cells followed by CD56+ T
cells, monocytes, CD4- T cells and ﬁnally CD4+ T cells, which
exhibited the lowest values. Overall, the same pattern (with NK
cells having the highest relative CD69 MFI values) was also
observed after stimulation with the capsules. In general, CWPS was
a stronger stimulator than the capsules, although CWPS was
included as a positive control and statistical comparisons were
only carried out between the capsules.a measure of cell activation after in vitro stimulation. Whole blood from healthy non-
igure part B, N = 9) with pneumococcal C-polysaccharide (CWPS) and pneumococcal
d as negative control and stimulation with LPS as positive control (data not shown).
elative MFI, for the respective cell subsets indicated above each graph. Statistical
, type 9 and type 23).
Figure 3. (Continued ).
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above mentioned ﬁve cell subsets after 4 h, and four cell subsets
after 12 h; these are the nine tests referred to below. Among the
investigated capsules, type 23 was the strongest stimulator
followed by type 9 and type 3 respectively. A statistically
signiﬁcant difference was detected between type 3 and type
23 in eight out of nine (8/9) tests and between type 3 and type 9 in
seven of nine (7/9) tests. Between type 9 and type 23 a signiﬁcant
difference was shown only in three out of nine (3/9) tests. Results
were consistent, with small variations, at 4 and 12 hours.
3.2. Secreted cytokines
In contrast to unstimulated cells, stimulation with CWPS, type
3, type 9 and type 23 capsules, as well as the additional positive
control LPS, induced the release of cytokines IL-8, TNF, IL-10 and
IFNg (Figure 4), except for type 3 with regard to IFNg and IL-10,
and for type 9 with regard to IFNg.
After CWPS stimulation the highest cytokine concentration was
observed for IL-8, followed by IL-10, TNF and INFg. The capsules
type 9 and type 23 were shown to have a somewhat different
relative cytokine pattern. Both induced IL-8 to the highest
concentration, followed by TNF, IL-10 and IFNg. Type 3 capsule
exhibited a similar pattern but yielded a higher value for IL-10 than
TNF.
Generally, capsules type 9 and type 23 stimulated to a much
larger cytokine release than capsule type 3. Release of IL-8, TNF and
IL-10 differed signiﬁcantly between type 3 and type 23 capsules
and between type 3 and type 9 capsules respectively. No such
signiﬁcant difference was noted between capsules type 9 and type
23. For IFNg, no signiﬁcant differences between the capsules were
observed.4. Discussion
In this study, we investigated the effects of in vitro stimulation
of whole blood from healthy individuals with pneumococcal C-
polysaccharide (CWPS) and three different capsular types of
Streptococcus pneumoniae, all of which are included in the 23-
valent polysaccharide vaccine. We analyzed the degree of
activation (CD69 expression) of monocytes, T-cell subsets and
NK cells as well as cytokine secretion (TNF, IL-8, IL-10 and IFNg).
Our results show that CWPS as well as all included individual
capsules (serotypes 3, 9 and 23) induced activation of monocytes, T
cells and NK cells with few exceptions. CWPS provided the
strongest activation, compared to the examined capsules, both for
monocytes, T-cells and NK cells. In general (both for CWPS and the
capsules), NK cells were activated to the highest degree, followed
by CD56+ T cells and monocytes. The lowest grade of activation
was evoked in CD4- T cells and CD4+ T cells. Among the capsules
type 23 activated the immune cells to the highest degree, followed
by type 9 and type 3 capsules, and the same order of potency was
observed with regard to cytokine release.
Since both CWPS and the capsular polysaccharides were able to
stimulate a variety of immune cells, the question arises about
which mechanisms could be mediating this. CWPS is also known as
teichoic acid 4, structurally similar (especially in S. pneumoniae) to
lipoteichoic acid and a well-known ligand for TLR2 5. Toll-like
receptors (TLRs) are part of the innate immune system and
recognize conserved molecular patterns on various pathogens. LPS
(lipopolysaccharide) is an example and a ligand for TLR4, and was
used in this study as an additional positive control. CWPS also has
the property of being a so-called zwitter-ionic polysaccharide
(ZPS), i.e. it has a pattern of positive and negative charges in
repeating units, enabling it to directly stimulate T cells. 6 ZPS also
Figure 4. Cytokine concentrations of IL-8, TNF, IL-10 and IFNg in cell culture supernatants after 12 h in vitro stimulation of whole blood from healthy individuals. Cells were
stimulated with three different capsular polysaccharides (type 3, type 9, type 23), pneumococcal C-polysaccharide (CWPS), LPS and media alone (unstimulated). Bars show
mean values. Wilcoxon two sample test, *p < 0.05, **p < 0.01, ***p < 0.001, NS (non signiﬁcant). Statistical comparisons were only carried out between the three capsular
polysaccharides (type 3, type 9 and type 23). (Number of individuals included, N = 9).
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cells via action on antigen-presenting cells that has been shown
7. CWPS has several identical subunits which cross-links the B cell
receptor and elicits B cell proliferation.
Capsular polysaccharides are T cell independent B cell antigens,
and their capacity to induce protective antibody responses are the
reason they are used for vaccination. It is less clear how the
capsular polysaccharides may stimulate the immune cells
investigated in this study, since they have not been shown to be
ligands for TLRs 5,8. Only one of them, serotype 1 (not included in
this study), is a ZPS, and was shown to act both as a TLR2 ligand and
a direct T cell stimulator via a mechanism involving MHC class II
molecules on antigen-presenting cells 7,9. From studies in mice, it
has been shown that the polysaccharide vaccine contains both
TLR2 and TLR4 ligands. 5. It is known that even highly puriﬁed
pneumococcal capsular polysaccharides contain some amount of
CWPS 10. Thus it seems reasonable that CWPS may be an important
component involved in the activation and cytokine secretion
observed here. The amount of bound CWPS may vary depending on
the serotype. The CWPS also occurs in two forms, containing one or
two phosphorylcholine residues in the repeating unit.11
Direct TLR stimulation can only be expected to account for the
activation of some of the cells studied, however. Monocytes
express TLRs, and so do NK cells 12, as well as NK-like T cells 13, but
not ‘‘ordinary’’ (CD56-) CD4- T cells or CD4+ T cells.
An indirect activation e.g. by cytokines from other directly
activated cells may instead explain the stimulation of T cells notexpressing TLRs. During vaccination or a live S. pneumoniae
infection TLR-expressing cells such as dendritic cells and macro-
phages present in the tissues but not in peripheral blood are likely
to be activated in a way mirroring that of monocytes in the present
study. Most likely, a combination of direct and indirect (via cell-cell
contact or secreted mediators) activation of immune cells occurs.
Today two different types of pneumococcal vaccines are
available. One contains 23 different pneumococcal capsular
polysaccharides. The capsules crosslink the B cell receptors,
triggering antibody production. Antibodies to the capsules are
highly protective against lethal pneumococcal infections. The
other vaccine type, conjugated vaccine, contains 7 respectively
13 different capsular polysaccharides linked to a protein. The
protein is broken down to peptides which are presented by the B
cell to T cells, thereby inducing T cell help to generate plasma cell
differentiation and memory cell generation 14. The conjugated
vaccine, in contrast to the capsular–only containing vaccine,
induces different immunoglobulin IgG subclass patterns as a result
of the inﬂuences from T cell cytokines 15. Intriguingly, however,
immunoglobulin class switching from IgM to IgG also occurs in
response to the unconjugated polysaccharide vaccine. This is not
expected from a T cell independent (type 2 thymus-independent)
antigen. Therefore we speculate that the different potency of
capsular polysaccharides to stimulate potentially class switch
promoting T cells as well as non-T cells such as NK cells and
monocytes affects the outcome of vaccination with the conjugated
as well as the unconjugated vaccines. Among T cells, in particular
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CWPS. Furthermore, the capacity to induce IL-10 which could
negatively affect the impact of vaccination differs between the
capsules. Thus, the composition of the mixture of capsules used in
the conjugate vaccine may affect the levels of protective antibodies
generated by vaccination. Failure to develop signiﬁcant increases
in antibody concentration against speciﬁc serotypes after vaccina-
tion has been linked to pneumococcal pneumonia 16. Interestingly,
a previous study found that the T cell cytokine proﬁle and IgG
subclass response to conjugate vaccines was dependent on the
serotype of S. pneumoniae 15.
Although antibody-producing B cells provide the main protec-
tion induced by vaccination, other immune cells may contribute to
the defense against S. pneumoniae either directly or indirectly by
promoting B cell responses.
Studies have shown a role for CD8+ T cells to promote
protective antibody responses against pneumococci 17. Mice
lacking CD8 cannot produce pneumococcal polysaccharide anti-
bodies 18. The activation by CWPS and the capsules of the CD4- T
cell subset indicates that these agents activate CD8+ T cells, since
almost 90% of CD4- T cells were CD8+.
NK cells were strongly activated both by CWPS and by the
capsules. Several studies have shown that NK cells stimulate B cells
to antibody secretion and isotype switch and this has also been
observed after pneumococcal vaccination 8,19,20. In the case of NK
cell deﬁciency, B cells cannot switch serotype production 20.
The cytokines analyzed in this study were chosen to give a
broad overview of pro- and anti-inﬂammatory mediators. We
found that the capsules differed sharply in their capacity to induce
cytokine secretion from blood cells. It is likely that such
differences between capsules apply also to other cytokines. In
the in vitro stimulation in our experiments using whole blood, TNF
was probably produced by a variety of cell types such as
monocytes, neutrophils, CD4 + T cells and NK cells. TNF has
many pro-inﬂammatory effects and is involved in acute phase
reactions. INFg can be produced by activated T cells and NK cells
and activates macrophages to increased phagocytosis and
cytokine synthesis. IL-8 can be produced by monocytes and
attracts neutrophils. IL-10 is produced by e.g. T cells and
monocytes. It is an anti-inﬂammatory cytokine, which inhibits
e.g. T cell responses. In vivo other cells such as macrophages
(derived from monocytes) may also be triggered by pneumococcal
components to cytokine secretion.
Generally, the efﬁcacy of vaccine responses is evaluated by
measurement of the total IgG concentration in serum. In the
present study, we have performed a more detailed analysis on
various capsular inﬂuences on different immune cells and
cytokines. Immune cell subsets were activated by CWPS and the
investigated capsules, but to different degrees, with NK cells and
NK-like T cells, followed by monocytes, showing the strongest
signs of activation. Among the three capsules, capsule type
23 induced the strongest activation, followed by type 9 and type
3. This may be due to the different capsules´ inherent different
abilities to activate the immune cells. The cytokine release
followed the same pattern of relative potency among the capsules.
Since the three capsules were randomly chosen, we believe such
differences in immunostimulatory capacity would be observed
also for other capsules.
5. Conclusion
By differentiating the various immune responses to different
vaccine components, the results presented in this study increase
the understanding of how human immune cells react upon
pneumococcal vaccination and upon exposure to pneumococci.
The results shows that monocytes, NK cells, NK-like T cells, CD4+ Tcells and CD4- T cells are activated by exposure to capsular
polysaccharides, but to different degrees and that there are
variations in stimulatory capacity of vaccine capsular components.
These cell types may contribute to the immune defence against
pneumococcal infection by helping B cells produce antibodies, and
by inducing immunoglobulin class switching, a puzzling phenom-
enon in the context of T-cell independent antigens such as capsular
polysaccharides, but which our data may help explain. These
results may also help explain variations in efﬁcacy of vaccine
capsular components (serotype-speciﬁc responses) and contribute
to future vaccine development against pneumococcal and other
diseases.
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